On the public citation graph
Targeting the bone microenvironment in multiple myeloma
0 signed · 104 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/ajh.20961openalex-snapshot
Predictive value of alkaline phosphatase for response and time to progression in bortezomib‐treated multiple myeloma patients
inferredcites →https://doi.org/10.1002/ajh.2830390303openalex-snapshot
Radioimmunoassay for the measurement of serum IL‐6 and its correlation with tumour cell mass parameters in multiple myeloma
inferredcites →https://doi.org/10.1002/cncr.20652openalex-snapshot
Incidence of multiple myeloma in Olmsted County, Minnesota
inferredcites →https://doi.org/10.1002/ijc.22033openalex-snapshot
Serum concentrations of Dickkopf‐1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation
inferredcites →https://doi.org/10.1007/s10585-006-9038-6openalex-snapshot
Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model
inferredcites →https://doi.org/10.1016/j.bcmd.2004.01.001openalex-snapshot
Pathogenesis of myeloma bone disease
inferredcites →https://doi.org/10.1016/j.bcmd.2004.04.012openalex-snapshot
Myeloma cells (5TMM) and their interactions with the marrow microenvironment
inferredcites →https://doi.org/10.1016/j.exphem.2004.03.015openalex-snapshot
New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-κB ligand (RANKL)
inferredcites →https://doi.org/10.1016/j.exphem.2004.11.015openalex-snapshot
MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells
inferredcites →https://doi.org/10.1016/j.gene.2004.06.044openalex-snapshot
Wnt signaling in osteoblasts and bone diseases
inferredcites →https://doi.org/10.1016/s0006-291x(02)02951-0openalex-snapshot
Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction
inferredcites →https://doi.org/10.1016/s0885-3924(02)00478-5openalex-snapshot
Clinical Evaluation of Onset of Analgesia Using Intravenous Pamidronate in Metastatic Bone Pain
inferredcites →https://doi.org/10.1016/s1079-9796(04)00096-8openalex-snapshot
Erratum to ?Pathogenesis of myeloma bone disease? 6Blood Cells Mol. Dis. 32 (2004) 290?2929
inferredcites →https://doi.org/10.1016/s1359-6349(09)72055-5openalex-snapshot
20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
inferredcites →https://doi.org/10.1023/a:1008238422151openalex-snapshot
Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease
inferredcites →https://doi.org/10.1034/j.1600-0609.2000.90074.xopenalex-snapshot
Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma
inferredcites →https://doi.org/10.1038/sj.leu.2404806openalex-snapshot
Bortezomib inhibits human osteoclastogenesis
inferredcites →https://doi.org/10.1046/j.1365-2141.1998.00687.xopenalex-snapshot
Interleukin‐6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance
inferredcites →https://doi.org/10.1046/j.1365-2141.2000.01845.xopenalex-snapshot
Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts
inferredcites →https://doi.org/10.1046/j.1365-2141.2002.03824.xopenalex-snapshot
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma
inferredcites →https://doi.org/10.1046/j.1365-2141.2002.03826.xopenalex-snapshot
Nephrotic proteinuria associated with high‐dose pamidronate in multiple myeloma
inferredcites →https://doi.org/10.1056/nejmoa030847openalex-snapshot
The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma
inferredcites →https://doi.org/10.1073/pnas.201394498openalex-snapshot
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
inferredcites →https://doi.org/10.1080/10428190701648281openalex-snapshot
Myeloma cells and bone marrow osteoblast interactions: Role in the development of osteolytic lesions in multiple myeloma
inferredcites →https://doi.org/10.1111/j.0105-2896.2005.00323.xopenalex-snapshot
The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma
inferredcites →https://doi.org/10.1111/j.1365-2141.2004.05207.xopenalex-snapshot
A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK
inferredcites →https://doi.org/10.1111/j.1365-2249.1993.tb05943.xopenalex-snapshot
Cytokines involved in the progression of multiple myeloma
inferredcites →https://doi.org/10.1111/j.1600-0609.1992.tb00046.xopenalex-snapshot
Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption
inferredcites →https://doi.org/10.1111/j.1600-0609.2008.01065.xopenalex-snapshot
Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myeloma
inferredcites →https://doi.org/10.1158/0008-5472.can-06-4666openalex-snapshot
Production of Wnt Inhibitors by Myeloma Cells: Potential Effects on Canonical Wnt Pathway in the Bone Microenvironment
inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-1933openalex-snapshot
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
inferredcites →https://doi.org/10.1172/jci0215687openalex-snapshot
Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency
inferredcites →https://doi.org/10.1172/jci15687openalex-snapshot
Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency
inferredcites →https://doi.org/10.1177/216507996801601208openalex-snapshot
1969 Cancer Facts and Figures
inferredcites →https://doi.org/10.1182/blood-2002-01-0148openalex-snapshot
Immunocytochemistry reveals RANKL expression of myeloma cells
inferredcites →https://doi.org/10.1182/blood-2002-04-1121openalex-snapshot
Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease
inferredcites →https://doi.org/10.1182/blood-2003-01-0016openalex-snapshot
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis
inferredcites →https://doi.org/10.1182/blood-2003-06-1992openalex-snapshot
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
inferredcites →https://doi.org/10.1182/blood-2003-11-3839openalex-snapshot
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
inferredcites →https://doi.org/10.1182/blood-2004-12-4940openalex-snapshot
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
inferredcites →https://doi.org/10.1182/blood-2004-12-4986openalex-snapshot
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
inferredcites →https://doi.org/10.1182/blood-2005-03-1080openalex-snapshot
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
inferredcites →https://doi.org/10.1182/blood-2006-11-059188openalex-snapshot
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
inferredcites →https://doi.org/10.1182/blood-2007-03-067710openalex-snapshot
Myeloma bone disease and proteasome inhibition therapies
inferredcites →https://doi.org/10.1182/blood-2007-05-093294openalex-snapshot
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
inferredcites →https://doi.org/10.1182/blood-2008-01-132134openalex-snapshot
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
inferredcites →https://doi.org/10.1182/blood.v104.11.2356.2356openalex-snapshot
Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.
inferredcites →https://doi.org/10.1182/blood.v110.11.3604.3604openalex-snapshot
An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed (R) or Plateau-Phase (PP) Multiple Myeloma (MM).
inferredcites →https://doi.org/10.1182/blood.v73.7.1915.1915openalex-snapshot
Response patterns of purified myeloma cells to hematopoietic growth factors
inferredcites →https://doi.org/10.1182/blood.v96.2.671openalex-snapshot
Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma
inferredcites →https://doi.org/10.1182/blood.v98.3.771openalex-snapshot
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays
inferredcites →https://doi.org/10.1359/jbmr.041131openalex-snapshot
Fracture Risk With Multiple Myeloma: A Population-Based Study
inferredcites →https://doi.org/10.1532/ijh97.07030openalex-snapshot
Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma
inferredcites →https://doi.org/10.1634/stemcells.2005-0220openalex-snapshot
A Crosstalk Between Myeloma Cells and Marrow Stromal Cells Stimulates Production of DKK1 and Interleukin-6: A Potential Role in the Development of Lytic Bone Disease and Tumor Progression in Multiple Myeloma
inferredcites →https://doi.org/10.1681/asn.v1261164openalex-snapshot
Collapsing Focal Segmental Glomerulosclerosis Following Treatment with High-Dose Pamidronate
inferredcites →https://doi.org/10.4049/jimmunol.143.10.3211openalex-snapshot
IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells.
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4149831openalex-extracted
NCX1 Disturbs Calcium Homeostasis, and Promotes RANKL-Induced Osteoclast Differentiation by Regulating JMK/ C-Fos/NFATc1 Signaling Pathway in Multiple Myeloma
inferred← citeshttps://doi.org/10.1002/hon.2493openalex-snapshot
Chemical and thyroid hormone profile of the bone marrow interstitial fluid in hematologic disorders and patients without primary hematologic disorders
inferred← citeshttps://doi.org/10.1002/jbm4.10186openalex-snapshot
The Emerging Role of Osteocytes in Cancer in Bone
inferred← citeshttps://doi.org/10.1007/978-1-4614-4666-8_8openalex-snapshot
The Bone Marrow Microenvironment: Novel Targets to Circumvent Minimal Residual Disease and Drug Resistance in Multiple Myeloma
inferred← citeshttps://doi.org/10.1007/978-94-007-5028-9_4openalex-snapshot
Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy
inferred← citeshttps://doi.org/10.1007/s00109-015-1345-4openalex-snapshot
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities
inferred← citeshttps://doi.org/10.1007/s10238-022-00905-1openalex-snapshot
NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma
inferred← citeshttps://doi.org/10.1007/s10863-012-9412-9openalex-snapshot
Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate
inferred← citeshttps://doi.org/10.1007/s11914-021-00679-7openalex-snapshot
Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease
inferred← citeshttps://doi.org/10.1007/s12018-017-9227-7openalex-snapshot
Osteocytes and Their Messengers as Targets for the Treatment of Multiple Myeloma
inferred← citeshttps://doi.org/10.1007/s12307-011-0086-3openalex-snapshot
The Immune Microenvironment of Myeloma
inferred← citeshttps://doi.org/10.1016/b978-0-12-801238-3.11258-9openalex-snapshot
Myeloma Bone Disease
inferred← citeshttps://doi.org/10.1016/j.abb.2014.07.013openalex-snapshot
Cancer and bone: A complex complex
inferred← citeshttps://doi.org/10.1016/j.clml.2012.01.006openalex-snapshot
TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target
inferred← citeshttps://doi.org/10.1016/j.micron.2017.01.009openalex-snapshot
Altered bone microarchitecture and gene expression profile due to calcium deficiency in a mouse model of myeloma
inferred← citeshttps://doi.org/10.1038/leu.2011.60openalex-snapshot
The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells
inferred← citeshttps://doi.org/10.1038/leu.2013.24openalex-snapshot
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction
inferred← citeshttps://doi.org/10.1038/leu.2017.152openalex-snapshot
Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth
inferred← citeshttps://doi.org/10.1039/c5lc00341eopenalex-snapshot
Well plate-based perfusion culture device for tissue and tumor microenvironment replication
inferred← citeshttps://doi.org/10.1089/ten.tec.2013.0490openalex-snapshot
Patient-Specific 3D Microfluidic Tissue Model for Multiple Myeloma
inferred← citeshttps://doi.org/10.1097/spc.0000000000000090openalex-snapshot
Role of osteocytes in multiple myeloma bone disease
inferred← citeshttps://doi.org/10.1097/spc.0b013e32834a76edopenalex-snapshot
Current World Literature
inferred← citeshttps://doi.org/10.1111/bjh.12270openalex-snapshot
Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease
inferred← citeshttps://doi.org/10.1155/2014/864058openalex-snapshot
The Genetic Architecture of Multiple Myeloma
inferred← citeshttps://doi.org/10.1158/0008-5472.c.6513220.v1openalex-snapshot
Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
inferred← citeshttps://doi.org/10.1158/0008-5472.can-15-1703openalex-snapshot
Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
inferred← citeshttps://doi.org/10.1158/0008-5472.can-21-0524openalex-snapshot
Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
inferred← citeshttps://doi.org/10.1172/jci61188openalex-snapshot
Molecular pathogenesis of multiple myeloma and its premalignant precursor
inferred← citeshttps://doi.org/10.1186/1756-8722-6-92openalex-snapshot
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
inferred← citeshttps://doi.org/10.1186/s12964-018-0280-8openalex-snapshot
TRPV2-induced Ca2+-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma
inferred← citeshttps://doi.org/10.1186/s12964-021-00781-4openalex-snapshot
Pathophysiological role of calcium channels and transporters in the multiple myeloma
inferred← citeshttps://doi.org/10.1189/jlb.3mr1116-468ropenalex-snapshot
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche
inferred← citeshttps://doi.org/10.13130/colombo-michela_phd2014-01-27openalex-snapshot
RATIONALE FOR A NOTCH-DIRECTED THERAPY TO PREVENT MULTIPLE MYELOMA CROSSTALK WITH THE OSTEOCLASTOGENIC NICHE
inferred← citeshttps://doi.org/10.1371/journal.pone.0016078openalex-snapshot
The Role of the BMP Signaling Antagonist Noggin in the Development of Prostate Cancer Osteolytic Bone Metastasis
inferred← citeshttps://doi.org/10.1371/journal.pone.0143206openalex-snapshot
Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts
inferred← citeshttps://doi.org/10.1532/lh96.09013openalex-snapshot
Detection of Morphologic Changes in Peripheral Mononuclear Cells in Hepatitis B Virus Infection Using the Beckman Coulter LH 750
inferred← citeshttps://doi.org/10.1532/lh96.11003openalex-snapshot
Biology and Bioinformatics of Myeloma Cell
inferred← citeshttps://doi.org/10.18632/oncotarget.12643openalex-snapshot
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications
inferred← citeshttps://doi.org/10.2174/1871530320999200818102731openalex-snapshot
Role of MIF-173G/C and Mbl2 Codon 54A/B Variants in the Risk of Multiple Myeloma: An Association Study
inferred← citeshttps://doi.org/10.3109/10428194.2013.778409openalex-snapshot
Macrophages in multiple myeloma: emerging concepts and therapeutic implications
inferred← citeshttps://doi.org/10.3109/10428194.2015.1004168openalex-snapshot
Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma
inferred← citeshttps://doi.org/10.3324/haematol.2016.154062openalex-snapshot
Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression
inferred← citeshttps://doi.org/10.3389/fmed.2017.00092openalex-snapshot
Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response
inferred← citeshttps://doi.org/10.3390/ijms22073389openalex-snapshot
Management of Myeloma Bone Lesions
inferred← citeshttps://doi.org/10.4081/hr.2018.7401openalex-snapshot
Bone-targeted agents in multiple myeloma
inferred← citeshttps://doi.org/10.4155/fmc.11.144openalex-snapshot
Therapeutic Potential of Ccr1 Antagonists for Multiple Myeloma
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.